Bitopertin - Disc Medicine
Alternative Names: DISC-1459; Heme synthesis modulator - Disc Medicine; R-1678; RG 6718; RG-6178; RG1678; RO-4917838Latest Information Update: 13 Aug 2024
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Disc Medicine; Roche
- Class Antianaemics; Antipsychotics; Behavioural disorder therapies; Piperazines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Erythropoietic protoporphyria
- Phase I/II Diamond-Blackfan syndrome
- Preclinical Myelodysplastic syndromes
- Discontinued Beta-thalassaemia; Obsessive-compulsive disorders; Schizophrenia
Most Recent Events
- 08 Aug 2024 Disc Medicine expects the "End of phase II meeting" to discuss optimal registrational endpoints moving forward in Erythropoietic protoporphyria (EPP) to occur in the second half of 2024
- 14 Jun 2024 Efficacy data from a phase II AURORA trial in Erythropoietic protoporphyria released by Disc Medicine
- 09 May 2024 The US FDA grants Rare Pediatric Disease Designation (RPD) to Bitopertin for the treatment of Erythropoietic protoporphyria